Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.20338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographics and clinical outcomes of patients with acute heart failure : The Acute Heart Failure Registry from the Clinic Ottakring (AHF-COR Registry).
Wien Klin Wochenschr
September 2025
3rd Medical Department with Cardiology and Intensive Care Medicine, Clinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Background: Acute heart failure (AHF) significantly contributes to cardiovascular morbidity and mortality, bearing a substantial socioeconomic burden. While the dynamics of chronic heart failure have been extensively explored in global patient cohorts, comprehensive data specific to AHF remain limited.
Methods: This retrospective, single-center, real-world study comprises hospitalized patients with AHF, admitted to a tertiary care hospital in Vienna, Austria, between 1 January 2012 and 31 December 2019.
Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patients.
Ann Hematol
September 2025
Faculty of Medicine, Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
The development of pulmonary hypertension (PH) after splenectomy is one of the recently controversial issues. This study aims to investigate whether splenectomy itself is an independent risk factor for the development of PH or if the primary contributor to PH development is the underlying condition that necessitated splenectomy. This study was conducted prospectively.
View Article and Find Full Text PDFCirculating metabolites in patients with chronic heart failure are not related to gut leakage or gut dysbiosis.
PLoS One
September 2025
Department of Cardiology Ullevaal, Oslo University Hospital, Oslo, Norway.
Background: The gut microbiota produces numerous metabolites that can enter the circulation and exert effects outside the gut. Several studies have reported altered gut microbiota composition and circulating metabolites in patients with chronic heart failure (HF) compared to healthy controls. Limited data is available on the interplay between dysbiotic features of the gut microbiota and altered circulating metabolites in HF patients.
View Article and Find Full Text PDFA novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction.
ESC Heart Fail
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, UK.
Aims: To help avoid therapeutic inertia, we developed a pragmatic treatment score (QUAD Score) for use in daily practice by healthcare professionals managing patients with a left ventricular ejection fraction (LVEF) < 50% and heart failure. We now investigate the association between achieved QUAD scores and 1 year outcomes.
Methods: This was a multicentre cohort study in consecutive patients with incident heart failure and LVEF <50%, who completed therapy titration between January 2021 and June 2023.
The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
Eur J Heart Fail
September 2025
Cardiology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.
Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.